Introduction: Medication adherence is critical in chronic immune-mediated inflammatory
diseases (IMIDs) and could be affected by patients' treatment-related beliefs. The objective of this study was to determine beliefs about systemic medications in patients with IMIDs and to explore the association of those beliefs and other factors with adherence.
Methods:
This was a multi-country, cross-sectional, self-administered survey study. [4] [5] [6] , lower quality of life [7] , and risk of hospitalization or prolongation of hospital stay [8] [9] [10] , resulting in increased healthcare resource use and costs [8] [9] [10] [11] [12] .
According to the World Health
Organization, adherence to long-term therapy is defined as the degree to which a person's use of medication, following a diet, and/or adopting lifestyle changes is consistent with agreed-upon recommendations from a healthcare provider [13] . 
RESULTS

Disease and Patient Characteristics
Patient Demographics
ALIGN enrolled 7328 patients from 34 countries; data from 7197 patients enrolled in 33 countries who provided documentation for at least one questionnaire were used in the analysis. Patients were recruited from four different regions (Fig. S1) ; 56.8% of the patients were recruited in Western Europe and Canada. The percentages of female patients in the study varied depending on the IMID; mean ages ranged from 38.0 years (CD) to 54.8 years (RA; Table 1 ). Additional patient characteristics are summarized in Table S2 .
Disease Characteristics
The mean duration of disease varied across the six IMIDs (Table 1) . Prior to the start of current IMID treatment, 68.8% of the patients had a disease severity rated as moderate to severe or severe, whereas under their current therapies, only 12.2% had disease severity rated as moderate to severe or severe ( Table S2 .
Beliefs Towards Medication and Treatment Adherence
Specific Beliefs Towards Current IMID Medications
BMQ-Specific Necessity subscale scores indicated a relatively high perceived need for current treatment ( Fig. 1a ; Table S3a ). Numerically higher mean scores were reported for patients receiving TNFi (either as monotherapy or as a combination therapy) compared with conventional therapy alone. BMQ-Specific Concerns subscale scores were lower than those observed for the BMQ-Specific Necessity subscale, and were in a similar range across the three treatment groups ( Fig. 1a, b ; Tables S3a, b) . 
Beliefs About Medications in General
According to BMQ-General subscale results covering general medication overuse and harm beliefs (Table S1b) , we found a significant proportion of patients with negative beliefs about medication in general (e.g., perception
of ''all medicines to be poison'' [9.0-20.3% of patients] and of ''most medicines to be addictive'' [14.6-24.0%]). These beliefs were highest in patients with RA and were lowest in patients with CD and UC (Table S4) . Agreement with the belief that ''physicians place too much trust on medicines'' ranged from 28.4% to 45.6%, depending on the specific IMID. Up to 28.2% of patients believed that they ''should stop their treatment for a while every now and (Table S5) .
The percentage of patients with signs and symptoms suggestive of depression (PHQ-2 total score C4) ranged from 13.7% (CD) to 20.5% (RA ; Table S6 ). (Fig. 2) . The lowest rate of highly adherent patients was observed in the AS population receiving conventional medication, either alone (28.4%) or in combination therapy (33.1%; Fig. 2 ). PS psoriasis, PsA psoriatic arthritis, RA rheumatoid arthritis, TNFi tumor necrosis factor inhibitor, UC ulcerative colitis. TNFi mono valid data for n = 2277, missing data for n = 24, TNFi combo -TNFi rating valid data for n = 1940, missing data for n = 57, TNFi combo -Conventional rating valid data for n = 1918, missing data for n = 79, Conventional only valid data for n = 2861, missing data for n = 38 (Table S7 ). Higher scores on the BIPQ [19, 20] .
Self-Reported Adherence
In ALIGN, perceptions about the necessity of the medication rather than concern beliefs affected high medication adherence in a majority of the IMIDs. These observations are consistent with results from four [19, 20, 37, 38] of the six [19, 20, 28, [37] [38] [39] [18, [39] [40] [41] [42] [43] [44] . In our study, Caucasians in general harbored significantly less concerns and overuse beliefs but not higher treatment necessity beliefs compared with non-Caucasians.
One limitation of the ALIGN study was that illness perception, beliefs about medication, risk of depression, and adherence results were based on self-reported outcomes that may be influenced by self-presentational and recall biases. Patients may overestimate the extent of their adherence in an attempt to ''please the doctor,'' or if they believe that admitting to non-adherence may result in adverse judgments.
However, in our study patients' responses were confidential; thus, the risk of overestimating adherence to ''please the doctor'' was reduced.
Another caveat is that the patients' responses to the specific questions in the questionnaires used in this study may not capture all the complexities of patients' feelings. Additionally, for feasibility reasons, no validated clinical scores were used to assess disease severity or response to therapy, and no uniform definitions or confirmations were used for diagnosing the IMIDs. Furthermore, confounding factors (e.g., disease severity, treatment response, and number of co-morbidities) may not be equally distributed between the groups being compared in this non-randomized study, which could lead to bias and subsequent misinterpretation.
However, in our multivariable regression analyses, we controlled for various confounding factors so that such effects would be minimized and false interpretation could be avoided. 
